Pharming Group NV announced that it has entered into an exclusive distribution agreement with Cytobioteck S.A.S. (“Cytobioteck”), a privately owned Bogota, Colombia based specialty healthcare company, for the distribution of RUCONEST® (recombinant human C1 inhibitor) for the treatment of acute attacks of Hereditary Angioedema (HAE) in Colombia and Venezuela.
Pharming Group N.V. and Clinigen Group plc have entered into an international global access collaboration for HAEi, the International Patient Organization for C1- Inhibitor Deficiencies. The “HAEi GAP” program will provide access to RUCONEST® (conestat alfa) to eligible patients with hereditary angioedema (HAE), who currently do not have access to effective medication to treat acute attacks of the disease.
New Peer-Reviewed Publication Provides Further Insights into Mechanism of ISA Pharmaceuticals’ SLP® ImmunotherapeuticsPublished : Tuesday, May 12, 2015
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, announced the publication of a new peer-reviewed paper* demonstrating a beneficial effect of Synthetic Long Peptide (SLP®s) immunotherapeutics on intratumoral macrophages in cancers induced by human papilloma virus 16 (HPV16).
BaseClear and Bio Basic have signed a cooperation agreement in the field of synthetic biology. Thanks to this partnership BaseClear can now offer gene synthesis services at the best price in the market. BaseClear’s portfolio has also expanded with services for peptide synthesis, protein expression and purification, as well as a custom antibody service. BaseClear is the exclusive distributor of Bio Basic services and products within The Netherlands, Belgium, Italy and Scandinavia (Denmark, Sweden, Iceland, Norway, Finland).
On April 30th the yearly Technology for Health Expert meeting was held, this time hosted by the VU University Medical Center (VUMC) in Amsterdam. Wouter Bos, chairman of the VUMC, opened the meeting as keynote speaker and shared his vision with over 250 attendees on how healthcare will develop towards 2035. Subsequently the floor was open for 25 pitches, that covered a wide variety of topics and innovations.
CHDR and GBS: the first CRO/bioanalytical laboratory to qualify the in vivo endotoxin challenge as model for activation of the human vasculature, using Meso Scale Discovery’s Vascular Injury Panel I and the new V-plex™ Vascular Injury Panel II. Endotoxin exposure induces an inflammatory response characterized by increased cytokine levels. In addition, it activates the endothelium, the thin layer of squamous cells that lines the interior surface of blood vessels, to express various adhesion molecules. These molecules allow binding and migration of circulating immune cells to peripheral tissues.
The Faculty of Science of Leiden University opened up its research facilities by introducing the 'Open Access Research Infrastructure' (OARI) portal. The portal contains an online database with the available research instruments and related expertise. These are accessible to researchers of universities, other knowledge institutions and industry. The online database with more than 50 instruments has the ambition to grow into a (inter)national platform.
Facio Therapies and Evotec have entered into an agreement aimed at the identification of compounds showing activity as a potential treatment to stop the progression of FSHD. This agreement marks the start of finding a drug to overcome FSHD. Facio’s drug discovery program aims to identify compounds that increase the activity of SMCHD1 and restore the repression of DUX4. These compounds are so-called small molecules, relatively simple compounds that are manufactured by chemical synthesis.
The first course Biotechnology for non-biotechnologists organised by the Centrum Bioscience en Diagnostiek of Hogeschool Leiden at March 19th was a success. The participating non-biotech entrepreneurs and investors were enthusiastic about the course that they highly recommend to colleagues. So, join in for the next course at June 26th
> Read more in Dutch
BioMarin completes rolling NDA submission to FDA for Drisapersen for treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 SkippingPublished : Monday, April 27, 2015
BioMarin Pharmaceutical Inc. announced completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for drisapersen, an investigational exon-skipping drug candidate for the treatment of the largest genetically defined subset of Duchenne muscular dystrophy (DMD).
Galapagos NV announced that the selective JAK1 inhibitor filgotinib as once-daily monotherapy showed rapid improvements in signs and symptoms of moderately severe, active rheumatoid arthritis (RA) and met key efficacy endpoints after 12 weeks of treatment in the DARWIN 2 Phase 2B study. The study achieved its primary endpoint at all doses and demonstrated statistically significant improvements in ACR20 response versus placebo after 12 weeks of treatment. In addition, statistically significant ACR50 response and DAS28(CRP) decrease were achieved with all dose levels. Filgotinib was well tolerated in this study. Hemoglobin levels increased. These first 12 week results in the ongoing 24 week study are consistent with the efficacy and safety profile of filgotinib observed in prior clinical studies.
Batavia Bioservices announced its decision to change its name to Batavia Biosciences as of April 23, 2015. The change will coincide with the launch of a new website and multimedia communication strategy. Since its establishment in 2009, the company has experienced rapid growth and has established itself as a globally recognised and reliable partner for biotech companies, large pharmaceutical companies, government agencies, and academia.
Willem te Beest, vice-president of Leiden University and president of the Leiden Bio Science Park foundation, will hand over a micro-3D-portrait of the King printed by student entrepreneurs to the major of Leiden Henri Lenfernik on Kings Day 2015. This portrait of Willem-Alexander – as small as a salt crystal – produced by Leiden based Idris Solutions shows the scale on which this new technique of micro-3D-printing can work.
> Read more in Dutch
At AREA071 in Leiderdorp, the first Dutch Startup Experience will take place on the 23rd and 24th of April. Fifty students from a variety of disciplines will work in teams and address a social issue. The program, which was developed by Silicon valley entrepreneur and internationally renowned universities, is offered by Leiden University of Applied Sciences of and Leiden University. Want to know more? Check this!
> Read more in Dutch
In April Leiden Bio Science Park and InnovationQuarter explored investment potential and strengthen ties in the Life Science Sector in Korea and Taiwan. Leiden Bio Science Park and InnovationQuarter participated in Bio Korea partnering event and had the opportunity to promote the Dutch Life Science cluster and Medical Delta / Leiden Bio Science Park at the Gangwon Bio Business Partnering at the invitation of Chuncheon Bioindustry Foundation. Ellen Smit, senior account manager of Leiden Bio Science Park, was invited to speak.
Galapagos' JAK1 inhibitor filgotinib (GLPG0634) meets primary and other key efficacy endpoints after 12 weeks of treatment in DARWIN 1 Phase 2B studyPublished : Tuesday, April 14, 2015
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe